Evidence map›Paper›PMID 27861288›Full record

ReviewTransplantation2016

Innate Immune Regulations and Liver Ischemia-Reperfusion Injury.

Ling Lu, Haoming Zhou, Ming Ni, Xuehao Wang, Ronald Busuttil, Jerzy Kupiec-Weglinski, Yuan Zhai

Open access · greenAbstract readReview
In one paragraph

Review in Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 167 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. The Role of Interferon Regulatory Factors in Liver Diseases.International journal of molecular sciences · 2024
    Review
  18. Review
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 4 countries.

Ling Lu1 Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA. 2 Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Haoming Zhou
Ming Ni
Xuehao Wang
Ronald Busuttil
Jerzy Kupiec-Weglinski
Yuan Zhai
University of California, Los Angeles · US

Funding

CXCL10/CXCR3 Signaling Regulates TLR4-Mediated Liver Inflamation and InjuryR01DK083408 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHAI, YUAN · 2010 to 2014
$1.6M
Kupffer Cell Necroptosis and Homeostatic Function in Liver Immune Responses against Ischemia Reperfusion InjuryR21AI126516 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHAI, YUAN · 2016 to 2017
$424k
NIAID NIH HHS R21 AI126516NIDDK NIH HHS R01 DK083408
6 · The paper itself

Abstract

Liver ischemia reperfusion activates innate immune system to drive the full development of inflammatory hepatocellular injury. Damage-associated molecular patterns (DAMPs) stimulate myeloid and dendritic cells via pattern recognition receptors (PRRs) to initiate the immune response. Complex intracellular signaling network transduces inflammatory signaling to regulate both innate immune cell activation and parenchymal cell death. Recent studies have revealed that DAMPs may trigger not only proinflammatory but also immune regulatory responses by activating different PRRs or distinctive intracellular signaling pathways or in special cell populations. Additionally, tissue injury milieu activates PRR-independent receptors which also regulate inflammatory disease processes. Thus, the innate immune mechanism of liver ischemia-reperfusion injury involves diverse molecular and cellular interactions, subjected to both endogenous and exogenous regulation in different cells. A better understanding of these complicated regulatory pathways/network is imperative for us in designing safe and effective therapeutic strategy to ameliorate liver ischemia-reperfusion injury in patients.

Indexed as

Immunity, InnateAnimalsDendritic CellsHMGB1 ProteinHumansImmunologic FactorsInflammationInterferonsIschemiaLiverMiceMyeloid CellsReceptors, Pattern RecognitionReperfusion InjurySignal TransductionToll-Like Receptor 4HMGB1 ProteinHMGB1 protein, humanImmunologic FactorsInterferonsReceptors, Pattern RecognitionTLR4 protein, humanToll-Like Receptor 4Tumor Necrosis Factor-alpha

Identifiers

PMID27861288
PMCPMC5141614
OpenAlexW2510497553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.